Refine
Year of publication
Language
- English (31)
Has Fulltext
- yes (31)
Is part of the Bibliography
- no (31)
Keywords
- Multiple sclerosis (2)
- Neuroinflammation (2)
- ceramides (2)
- inflammation (2)
- macrophage (2)
- pain (2)
- sphingolipids (2)
- sphingosine kinase (2)
- stroke (2)
- A498 cells (1)
- AMP-activated kinase (1)
- Acquired resistance (1)
- Acute lymphoblastic leukemia (1)
- Acute myeloid leukemia (1)
- Adenylyl cyclase (1)
- Autoimmune encephalomyelitis (1)
- Biomarkers (1)
- Brain injury (1)
- CNDAC (1)
- CTGF (1)
- CYP1A1 (1)
- Cancer (1)
- DCK (1)
- DNA damage (1)
- Diagnostic markers (1)
- Entorhinal cortex lesion (1)
- FTY720 (1)
- G-protein-coupled receptors (1)
- G2A (1)
- GEMs (1)
- GPCR (1)
- Glycolysis (1)
- Gαq/11 (1)
- HCC marker (1)
- HIV (1)
- HIV-1 (1)
- IFN-β (1)
- Intrinsic resistance (1)
- Leukemia (1)
- Lipid signaling (1)
- Lpar2 (1)
- Lysophosphatidic acids (1)
- MLV (1)
- MRP4 (1)
- Mitochondrial ROS (1)
- Nociception (1)
- Oncology (1)
- Oxidative phosphorylation (1)
- PKA (1)
- PRG-1 (1)
- RCC (1)
- S1P receptors (1)
- SAMHD1 (1)
- SAMHD1 knockout mouse (1)
- SAMHD1 phosphorylation (1)
- Sapacitabine (1)
- Spinal cord (1)
- Structural plasticity (1)
- T-cell homing (1)
- acute inflammation (1)
- adenosine receptors (1)
- analgesia (1)
- angiopoietin-like 3 (ANGPTL3) (1)
- beta blockade (1)
- bioactive lipids (1)
- bioactive phospholipids (1)
- biomarker (1)
- blood pressure (1)
- breast cancer (1)
- cAMP (1)
- caloric restriction (1)
- cannabinoid receptor type 1 (1)
- cortical network (1)
- data science (1)
- dendritic cells (1)
- eNPP2 (1)
- endocannabinoids (1)
- epigenetics (1)
- exercise (1)
- fibrosarcoma (1)
- glucose metabolism (1)
- graft rejection (1)
- hepatitis C (1)
- histone deacetylase (1)
- human pain models (1)
- human pharmacology (1)
- hyperglycemia (1)
- ischemic type biliary lesions (1)
- mast cells (1)
- microlesions (1)
- migration (1)
- multiple sclerosis (1)
- orthopic liver transplantation (1)
- perineurium (1)
- polarization (1)
- post-exercise hypotension (1)
- prostaglandin E (1)
- prostaglandins (1)
- psychiatric disorders (1)
- regulatory T helper cells (1)
- resolution (1)
- sciatic nerve (1)
- smooth muscle cells (1)
- sphingolipid (1)
- sphingosine 1-phosphate (1)
- sphingosine 1-phosphate homologues (1)
- sphingosine 1-phosphate receptor (1)
- sphingosine-1-phosphate (1)
- synapse (1)
- toll-like receptor (1)
- tumor pain (1)
- vascular biology (1)
- xenobiotics (1)
- fingolimod (1)
Institute
- Medizin (29)
- Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit (ZAFES) (6)
- Biochemie, Chemie und Pharmazie (2)
- Biowissenschaften (2)
- Pharmazie (2)
- Sonderforschungsbereiche / Forschungskollegs (2)
- Institut für Ökologie, Evolution und Diversität (1)
- Interdisziplinäres Zentrum für Neurowissenschaften Frankfurt (IZNF) (1)
- Senckenbergische Naturforschende Gesellschaft (1)
Sphingosine 1-phosphate (S1P) is a lipid mediator with numerous biological functions. The term ‘S1P’ mainly refers to the sphingolipid molecule with a long-chain sphingoid base of 18 carbon atoms, d18:1 S1P. The enzyme serine palmitoyltransferase catalyses the first step of the sphingolipid de novo synthesis using palmitoyl-CoA as the main substrate. After further reaction steps, d18:1 S1P is generated. However, also stearyl-CoA or myristoyl-CoA can be utilised by the serine palmitoyltransferase, which at the end of the S1P synthesis pathway, results in the production of d20:1 S1P and d16:1 S1P respectively. We measured these S1P homologues in mice and renal tissue of patients suffering from renal cell carcinoma (RCC). Our experiments highlight the relevance of d16:1 S1P for the induction of connective tissue growth factor (CTGF) in the human renal clear cell carcinoma cell line A498 and human RCC tissue. We show that d16:1 S1P versus d18:1 and d20:1 S1P leads to the highest CTGF induction in A498 cells via S1P2 signalling and that both d16:1 S1P and CTGF levels are elevated in RCC compared to adjacent healthy tissue. Our data indicate that d16:1 S1P modulates conventional S1P signalling by acting as a more potent agonist at the S1P2 receptor than d18:1 S1P. We suggest that elevated plasma levels of d16:1 S1P might play a pro-carcinogenic role in the development of RCC via CTGF induction.